NYS started screening for CF in October 2002 using a two-tier IRT-DNA algorithm consisting of first-tier immunoreactive trypsinogen (IRT) screening, followed by targeted screening using a CFTR variant panel for infants with IRT values in the daily top 5%. This evidence concerns the gene CFTR and cystic fibrosis.